Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NUVB
stocks logo

NUVB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
31.90M
+458.48%
-0.104
-30.37%
29.37M
+852.26%
-0.196
+22.5%
38.90M
+704.96%
-0.170
-0%
Estimates Revision
The market is revising Upward the revenue expectations for Nuvation Bio Inc. (NUVB) for FY2025, with the revenue forecasts being adjusted by 86.47% over the past three months. During the same period, the stock price has changed by 113.08%.
Revenue Estimates for FY2025
Revise Upward
up Image
+86.47%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.08%
In Past 3 Month
Stock Price
Go Up
up Image
+113.08%
In Past 3 Month
Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 10.38 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 10.38 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.310
sliders
Low
8.00
Averages
10.38
High
12.00
Current: 8.310
sliders
Low
8.00
Averages
10.38
High
12.00
Clear Street
Buy
maintain
$12
2025-11-26
Reason
Clear Street
Price Target
$12
2025-11-26
maintain
Buy
Reason
Clear Street reiterates a Buy rating and $12 price target on shares of Nuvation Bio after the company announced that it has discontinued development of NUV-1511, its lead DDC for advanced solid tumors. Clear Street does not view this as thesis-changing, telling investors in a research note that taletrectinib and safusidenib are distinct assets and that it expects blockbuster potential from taletrectinib and safusidenib's success, with pivotal trial completion in 2029, offers incremental upside to the firm's model.
Truist
Buy
initiated
$11
2025-11-24
Reason
Truist
Price Target
$11
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of Nuvation Bio with a Buy rating and $11 price target. Ibtrozi's FDA approvoal positions Nuvation Bio as a commercial-stage player in precision oncology, notes the analyst, who likes the launch set-up "led by a proven team" and supported by Ibtrozi's competitive profile in ROS1 non-small cell lung cancer.
Citizens JMP
Outperform
maintain
$8 -> $10
2025-11-20
Reason
Citizens JMP
Price Target
$8 -> $10
2025-11-20
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Nuvation Bio to $10 from $8 and keeps an Outperform rating on the shares. Safusidenib, in a Phase 2 Japanese glioma study, significantly outperformed based on overall response rate, compared to the Phase 3 INDIGO study of vorasidenib, the analyst tells investors in a research note. Nuvation Bio plans to move forward with safusidenib in a higher-grade glioma setting, which is a sensible path, Citizens says.
Wedbush
NULL -> Outperform
maintain
$7 -> $11
2025-11-19
Reason
Wedbush
Price Target
$7 -> $11
2025-11-19
maintain
NULL -> Outperform
Reason
Wedbush raised the firm's price target on Nuvation Bio to $11 from $7 and keeps an Outperform rating on the shares.
B. Riley
Buy
initiated
$12
2025-11-19
Reason
B. Riley
Price Target
$12
2025-11-19
initiated
Buy
Reason
B. Riley initiated coverage of Nuvation Bio with a Buy rating and $12 price target. The firm cites the company's positive commercial revenue ramp of its lead drug Ibtrozi within mutation-defined lung cancer for the Buy rating. The drug's "class-leading attributes are supporting robust early launch metrics," the analyst tells investors in a research note.
Citizens JMP
Outperform
maintain
$6 -> $8
2025-11-04
Reason
Citizens JMP
Price Target
$6 -> $8
2025-11-04
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Nuvation Bio to $8 from $6 and keeps an Outperform rating on the shares. Nuvation Bio reported Q4 financial results and highlighted 204 new Ibtrozi starts in Q3, the analyst tells investors in a research note. The launch trajectory is exceeding expectations and is already outpacing ROS1 launches in recent memory, Citizens says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nuvation Bio Inc (NUVB.N) is -14.27, compared to its 5-year average forward P/E of -8.98. For a more detailed relative valuation and DCF analysis to assess Nuvation Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.98
Current PE
-14.27
Overvalued PE
-1.18
Undervalued PE
-16.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
45.41
Current PS
0.00
Overvalued PS
229.94
Undervalued PS
-139.12
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 287.18% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 287.18% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

NUVB News & Events

Events Timeline

(ET)
2025-12-03
08:10:00
Nuvation Bio Publishes Phase 2 Study Results of Safusidenib
select
2025-11-26 (ET)
2025-11-26
12:35:47
Nuvation Bio Halts Development of NUV-1511
select
2025-11-03 (ET)
2025-11-03
16:15:23
Nuvation Bio Announces Q3 Earnings Per Share of 16 Cents, Exceeding Estimate of 15 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedNuvation Bio Stock Jumps 8.4% Following Encouraging Phase 2 Results for Grade-2 IDH1 Glioma

  • Stock Performance: Nuvation Bio Inc. (NUVB) shares rose 8.43% to $8.10 following positive Phase 2 clinical trial results for safusidenib in grade-2 IDH1-mutant glioma patients.

  • Clinical Trial Results: The trial data indicated promising safety and efficacy, suggesting a potential new treatment option in neuro-oncology.

  • Investor Reaction: The announcement led to increased trading activity, with stock volume significantly surpassing average levels.

  • Stock Range: Nuvation Bio's stock has a 52-week trading range of approximately $4.20 to $9.45.

[object Object]
Preview
5.0
12-04Yahoo Finance
Nuvation Bio Executive Offloaded Shares Valued at $1,173,255, Recent SEC Filing Reveals

  • Stock Sale Announcement: Dongfang Liu, the Chief Medical Officer of Nuvation Bio, sold 150,000 shares of the company on December 1, 2025.

  • Company Overview: Nuvation Bio is a biopharmaceutical company focused on developing innovative therapies for cancer treatment.

[object Object]
Preview
9.0
12-03Newsfilter
Nuvation Bio Reports 44% ORR for Safusidenib in Phase 2 Study
  • Significant Efficacy: In a Phase 2 study involving 27 patients with IDH1-mutant grade 2 gliomas, Safusidenib demonstrated an objective response rate (ORR) of 44.4%, indicating its potential to delay disease progression and provide new treatment options for patients.
  • Progression-Free Survival: As of the March 10, 2023 data cutoff, 87.9% of patients remained progression-free at 24 months, showcasing the long-term efficacy of Safusidenib, which may improve patients' quality of life and reduce long-term toxicities associated with chemotherapy.
  • Positive FDA Interactions: The study results support favorable interactions with the FDA, with plans to amend the G203 study into a pivotal trial for high-grade gliomas, potentially paving the way for regulatory approval and enhancing the company's competitiveness in oncology.
  • Good Safety Profile: While some mild to moderate adverse events were noted, with 18.5% of patients experiencing grade 3 or higher treatment-related adverse events, the overall safety profile was favorable, demonstrating the tolerability of Safusidenib and instilling confidence for future studies.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nuvation Bio Inc (NUVB) stock price today?

The current price of NUVB is 8.31 USD — it has decreased -0.72 % in the last trading day.

arrow icon

What is Nuvation Bio Inc (NUVB)'s business?

Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

arrow icon

What is the price predicton of NUVB Stock?

Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 10.38 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nuvation Bio Inc (NUVB)'s revenue for the last quarter?

Nuvation Bio Inc revenue for the last quarter amounts to 13.12M USD, increased 1704.68 % YoY.

arrow icon

What is Nuvation Bio Inc (NUVB)'s earnings per share (EPS) for the last quarter?

Nuvation Bio Inc. EPS for the last quarter amounts to -0.16 USD, increased 6.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nuvation Bio Inc (NUVB)'s fundamentals?

The market is revising Upward the revenue expectations for Nuvation Bio Inc. (NUVB) for FY2025, with the revenue forecasts being adjusted by 86.47% over the past three months. During the same period, the stock price has changed by 113.08%.
arrow icon

How many employees does Nuvation Bio Inc (NUVB). have?

Nuvation Bio Inc (NUVB) has 220 emplpoyees as of December 05 2025.

arrow icon

What is Nuvation Bio Inc (NUVB) market cap?

Today NUVB has the market capitalization of 2.85B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free